文献速递类风湿关节炎其他结缔组织病

免疫介导炎症性疾病中利妥昔单抗治疗相关免疫球蛋白缺陷与严重感染风险

Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease.
PubMed 文献 · RMD Open · 2024-01-30

该回顾性单中心观察性研究纳入311例接受至少一次利妥昔单抗输注的免疫介导炎症性疾病患者,10.6%存在治疗前免疫球蛋白缺陷、19.6%在随访期间出现获得性免疫球蛋白缺陷。随访期间14.5%发生严重感染,多因素分析显示严重感染与慢性肺病、糖皮质激素剂量及平均DAS28-C反应蛋白相关,时间依赖分析显示严重感染与获得性或治疗前免疫球蛋白缺陷均无关(校正HR 1.04,95%CI 0.5至2.3,p=0.92)。

要点

  • 311例中10.6%治疗前存在免疫球蛋白缺陷,19.6%随访期间出现获得性缺陷。
  • 随访期间14.5%发生严重感染,与免疫球蛋白缺陷无关(校正HR 1.04,95%CI 0.5至2.3,p=0.92)。
  • 严重感染与慢性肺病、糖皮质激素剂量及平均DAS28-C反应蛋白相关。

核心结论

  • 在免疫介导炎症性疾病患者中,严重感染风险与利妥昔单抗诱导的免疫球蛋白缺陷无关。
  • 利妥昔单抗管理应根据个体感染风险评估进行讨论,尤其是接受糖皮质激素治疗或患有慢性肺病的患者。

研究设计与样本

  • 观察性、回顾性单中心研究,纳入截至2020年5月31日接受至少一次利妥昔单抗输注的免疫介导炎症性疾病患者311例。
  • 末次输注后随访至少12个月,或随访至发生严重感染或死亡。
  • 免疫球蛋白缺陷分为治疗前已存在(利妥昔单抗前)和获得性(利妥昔单抗前免疫球蛋白检测正常但随访期间出现缺陷)。

主要发现

  • 311例患者中10.6%存在治疗前免疫球蛋白缺陷,19.6%出现获得性免疫球蛋白缺陷。
  • 治疗前免疫球蛋白缺陷与基线合并糖皮质激素治疗相关,尤其是基线高日剂量。
  • 获得性免疫球蛋白缺陷与利妥昔单抗累积剂量、平均DAS28、基线免疫抑制剂或糖皮质激素治疗、糖尿病和肥胖相关。
  • 随访期间14.5%的患者发生严重感染,治疗前免疫球蛋白缺陷患者中严重感染在数值上更常见但未达统计学显著。
  • 多因素分析显示严重感染风险与慢性肺病、糖皮质激素剂量和平均DAS28-C反应蛋白相关;时间依赖分析显示严重感染与获得性或治疗前免疫球蛋白缺陷均无关(校正HR 1.04,95%CI 0.5至2.3,p=0.92)。

关键数值与推荐

  • 严重感染与免疫球蛋白缺陷无关:校正HR 1.04(95%CI 0.5至2.3),p=0.92。
  • 随访期间严重感染发生率14.5%。
  • 治疗前免疫球蛋白缺陷发生率10.6%,获得性免疫球蛋白缺陷发生率19.6%。

临床怎么用

  • 原文结论认为利妥昔单抗管理应根据个体感染风险评估进行讨论,尤其是接受糖皮质激素治疗或患有慢性肺病的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We evaluated the risk of severe infection in patients with immune-mediated inflammatory disease (IMID) treated with RTX and with Ig deficiency. METHODS: This was an observational, retrospective single-centre study of patients undergoing treatment with at least one rituximab (RTX) infusion for an IMID until 31 May 2020. Patients were followed up for at least 12 months after the last infusion or until severe infection or death. Ig deficiency was classified as prevalent (before RTX) or acquired (normal Ig assay results before RTX but Ig deficiency during a follow-up). RESULTS: Of 311 patients, 10.6% had prevalent and 19.6% acquired Ig deficiency. Prevalent Ig deficiency was related to concomitant treatment with glucocorticoids (GCs), in particular with a high daily dose at baseline; and acquired Ig deficiency to cumulative dose of RTX, mean Disease Activity Score in 28 joints (DAS28), immunosuppressor or GCs therapy at baseline, diabetes mellitus and obesity. Overall, 14.5% of patients had a severe infection during follow-up, which was numerically but not statistically more frequent in patients with prevalent Ig deficiency than normal Ig level. On multivariate analysis, risk of severe infection was associated with chronic pulmonary disease, GCs dose and mean DAS28-C reactive protein. In a time-dependent analysis, risk of severe infection was not associated with Ig deficiency, either acquired or prevalent (adjusted HR 1.04 (95% CI 0.5 to 2.3), p=0.92). CONCLUSION: Risk of severe infection was not associated with RTX-induced Ig deficiency in patients with an IMID. RTX management should be discussed according to an individual assessment of the infectious risk, especially in patients with GC therapy or chronic lung disease.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Rempenault C, Lukas C, Tardivon L, et al. Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease. RMD Open. 2024. PMID: 38296311. doi:10.1136/rmdopen-2023-003415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。